Return On Equity of LIGAND PHARMACEUTICALS INC from 31 Mar 2013 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
LIGAND PHARMACEUTICALS INC quarterly and annual Return On Equity in % history and change rate from 31 Mar 2013 to 30 Sep 2025.
  • LIGAND PHARMACEUTICALS INC Return On Equity for the quarter ending 30 Sep 2025 was 6%, a 1.4% decline year-over-year.
  • LIGAND PHARMACEUTICALS INC annual Return On Equity for 2024 was -1%, a 106% decline from 2023.
  • LIGAND PHARMACEUTICALS INC annual Return On Equity for 2023 was 8%.
  • LIGAND PHARMACEUTICALS INC annual Return On Equity for 2022 was -4%, a 161% decline from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

LIGAND PHARMACEUTICALS INC Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2025 6% 0% -1.4% 01 Jul 2025 30 Sep 2025
Q2 2025 -9% -15% -261% 01 Apr 2025 30 Jun 2025
Q1 2025 -16% -30% -221% 01 Jan 2025 31 Mar 2025
Q4 2024 -1% -8% -106% 01 Oct 2024 31 Dec 2024
Q3 2024 6% +3% +126% 01 Jul 2024 30 Sep 2024
Q2 2024 6% +2% +43% 01 Apr 2024 30 Jun 2024
Q1 2024 14% +10% +305% 01 Jan 2024 31 Mar 2024
Q4 2023 8% +12% 01 Oct 2023 31 Dec 2023
Q3 2023 3% +5% 01 Jul 2023 30 Sep 2023
Q2 2023 4% +5% 01 Apr 2023 30 Jun 2023
Q1 2023 3% 0% +14% 01 Jan 2023 31 Mar 2023
Q4 2022 -4% -12% -161% 01 Oct 2022 31 Dec 2022
Q3 2022 -3% -12% -129% 01 Jul 2022 30 Sep 2022
Q2 2022 -1% -8% -115% 01 Apr 2022 30 Jun 2022
Q1 2022 3% -3% -47% 01 Jan 2022 31 Mar 2022
Q4 2021 7% +8% 01 Oct 2021 31 Dec 2021
Q3 2021 9% +11% 01 Jul 2021 30 Sep 2021
Q2 2021 7% +10% 01 Apr 2021 30 Jun 2021
Q1 2021 6% +13% 01 Jan 2021 31 Mar 2021
Q4 2020 0% -68% -101% 01 Oct 2020 31 Dec 2020
Q3 2020 -2% -70% -103% 01 Jul 2020 30 Sep 2020
Q2 2020 -3% -83% -104% 01 Apr 2020 30 Jun 2020
Q1 2020 -7% -111% -107% 01 Jan 2020 31 Mar 2020
Q4 2019 67% +43% +177% 01 Oct 2019 31 Dec 2019
Q3 2019 67% +41% +158% 01 Jul 2019 30 Sep 2019
Q2 2019 80% +50% +166% 01 Apr 2019 30 Jun 2019
Q1 2019 103% +69% +201% 01 Jan 2019 31 Mar 2019
Q4 2018 24% -12% -34% 01 Oct 2018 31 Dec 2018
Q3 2018 26% -23% -46% 01 Jul 2018 30 Sep 2018
Q2 2018 30% -2% -7.1% 01 Apr 2018 30 Jun 2018
Q1 2018 34% +24% +220% 01 Jan 2018 31 Mar 2018
Q4 2017 37% +37% 01 Oct 2017 31 Dec 2017
Q3 2017 49% +46% +1873% 01 Jul 2017 30 Sep 2017
Q2 2017 32% -36% -53% 01 Apr 2017 30 Jun 2017
Q1 2017 11% -90% -89% 01 Jan 2017 31 Mar 2017
Q4 2016 0% -152% -100% 01 Oct 2016 31 Dec 2016
Q3 2016 2% -230% -99% 01 Jul 2016 30 Sep 2016
Q2 2016 69% -6% -8% 01 Apr 2016 30 Jun 2016
Q1 2016 101% +75% +300% 01 Jan 2016 31 Mar 2016
Q4 2015 151% +127% +528% 01 Oct 2015 31 Dec 2015
Q3 2015 232% +220% +1794% 01 Jul 2015 30 Sep 2015
Q2 2015 75% +61% +455% 01 Apr 2015 30 Jun 2015
Q1 2015 25% +1% +3.8% 01 Jan 2015 31 Mar 2015
Q4 2014 24% -4% -13% 01 Oct 2014 31 Dec 2014
Q3 2014 12% -18% -59% 01 Jul 2014 30 Sep 2014
Q2 2014 13% -15% -53% 01 Apr 2014 30 Jun 2014
Q1 2014 24% +25% 01 Jan 2014 31 Mar 2014
Q4 2013 28% 01 Oct 2013 31 Dec 2013
Q3 2013 30% 01 Jul 2013 30 Sep 2013
Q2 2013 29% 01 Apr 2013 30 Jun 2013
Q1 2013 -1% 01 Jan 2013 31 Mar 2013

LIGAND PHARMACEUTICALS INC Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2024 -1% -8% -106% 01 Jan 2024 31 Dec 2024
2023 8% +12% 01 Jan 2023 31 Dec 2023
2022 -4% -12% -161% 01 Jan 2022 31 Dec 2022
2021 7% +8% 01 Jan 2021 31 Dec 2021
2020 0% -68% -101% 01 Jan 2020 31 Dec 2020
2019 67% +43% +177% 01 Jan 2019 31 Dec 2019
2018 24% +21% +654% 01 Jan 2018 31 Dec 2018
2017 3% +4% 01 Jan 2017 31 Dec 2017
2016 0% -152% -100% 01 Jan 2016 31 Dec 2016
2015 151% +127% +528% 01 Jan 2015 31 Dec 2015
2014 24% -4% -13% 01 Jan 2014 31 Dec 2014
2013 28% 01 Jan 2013 31 Dec 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.